The meeting of the committee included discussions concerning various bills primarily related to insurance policies, their regulations, and procedures. Notably, HB3812 was introduced to further streamline the prior authorization process in healthcare, enhancing the ease for practitioners to receive approvals for common procedures. The committee also deliberated over HB2213, which focused on the restructuring of the board of directors for the Texas Windstorm Insurance Association, and there was broad consensus to move it forward. Several other bills, such as HB2518, addressing installment premium payment plans for windstorm insurance, were also discussed and moved to be reported favorably without amendments.
The House Committee on Insurance convened to discuss multiple bills aimed at enhancing consumer protection and improving access to essential services. Notable discussions included HB2528, which seeks to eliminate prior authorization requirements for medications treating substance use disorders, thereby expediting access to crucial treatments for Texans. Representative Boosie laid out HB722, addressing transparency in auto insurance valuation processes, prompting engagement from various witnesses on how current practices potentially exploit consumers. Members voiced concerns about the intersection of bureaucratic delays and the urgency of addiction treatment, emphasizing the bill's potential life-saving implications.
Relating to out-of-pocket expense credits for payments made directly to a physician or health care provider by an enrollee of a governmental employee health benefit plan.
Relating to a group health benefit plan policy or contract holder's obligation to pay premiums on behalf of an individual after the individual's eligibility for group coverage terminates.
Relating to billing and reimbursement for certain medical equipment, devices, and supplies provided to Medicare enrollees; creating a criminal offense.
Relating to discriminatory practices by a health benefit plan issuer, pharmacy benefit manager, and third-party payor and certain prescription drug manufacturers, distributors, and related persons with respect to certain entities participating in a federal drug discount program; providing a civil penalty.